Vaccination is the most effective and best way to avoid the disease of COVID‐19 by Hadi Lotfi, Mina G. Mazar, Negar M. H. Ei, Mostafa Fahim, Nafiseh S. Yazdi

“…Among the inactive viral vaccines, the following can be mentioned: CoronaVac (Sinovac) WIBP vaccine (Wuhan Institute of Biological Products, Sinopharm), BBIBPCorV (Beijing Institute of Biological Products, Sinopharm), BBV152/Covaxin (Bharat Biotech, ICMR, National Institute of Virology) And among the protein‐based/subunit vaccines, the following can be counted: NVX‐CoV2373: (Novavax); SCB‐2019 vaccine (Clover Biopharmaceuticals AUS Pty Ltd.); Covax‐19 (GeneCure Biotechnologies; Vaxine Pty Ltd.) mRNA vaccines, viral vector vaccines, and protein subunit vaccines cannot cause disease because these vaccines stimulate the immune system to produce antibodies against virus proteins instead of the virus itself (or its antigen). …”
Get full text

Impact of a VI-polysaccharide conjugate vaccine in preventing Typhoid Fever in an endemic setting, Lalitpur, Nepal by Shakya, M

“…</p> <p>In this phase III participant-observer-blind randomized controlled trial, children aged 9 months to under-16 years old, were individually randomized (1:1) to either receive the TCV (Typbar-TCV, Bharat Biotech) or a capsular group A meningococcal conjugate vaccine (MenA) as control, and were followed-up for two years.…”

Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India by Priyamadhaba Behera, Arvind Kumar Singh, Sonu Hangma Subba, Arjun Mc, Dinesh Prasad Sahu, Pradnya Dilip Chandanshive, Somen Kumar Pradhan, Swayam Pragyan Parida, Abhisek Mishra, Binod Kumar Patro, Gitanjali Batmanabane

“…India approved COVID-19 vaccine called Covaxin, developed by the Indian Council of Medical Research and Bharat Biotech Ltd. The primary objective of the study was to estimate the effectiveness of Covaxin in preventing breakthrough SARS-CoV-2 infection in healthcare workers (HCWs). …”
Get full text

Thyroid Inconveniences With Vaccination Against SARS-CoV-2: The Size of the Matter. A Systematic Review by Verdiana Caironi, Fabián Pitoia, Pierpaolo Trimboli, Pierpaolo Trimboli

“…Regarding the vaccination received, 49.49% of patients received Comirnaty (Pfizer/BioNTech), 14.14% CoronaVac (Sinovac), 12.12% Vaxzevria (Oxford/Astrazeneca), 11.11% Spikevax (Moderna), 3.03% Ad26.COV2.S (Janssen, Johnson &amp; Johnson), one patient Covaxin (Bharat Biotech) and one patient Convidecia (Cansino). …”
Get full text

Inactivated vaccine Covaxin/BBV152: A systematic review by Tousief Irshad Ahmed, Saqib Rishi, Summaiya Irshad, Jyoti Aggarwal, Karan Happa, Sheikh Mansoor

“…We systematically reviewed and summarized studies focusing on Bharat Biotech’s Whole Virion Inactivated Corona Virus Antigen BBV152 (Covaxin), which is India’s indigenous response to fighting the SARS-CoV-2 pandemic. …”
Get full text

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial by Shakya, M, Voysey, M, Theiss-Nyland, K, Colin-Jones, R, Pant, D, Adhikari, A, Tonks, S, Mujadidi, YF, O'Reilly, P, Mazur, O, Kelly, S, Liu, X, Maharjan, A, Dahal, A, Haque, N, Pradhan, A, Shrestha, S, Joshi, M, Smith, N, Hill, J, Clarke, J, Stockdale, L, Jones, E, Lubinda, T, Bajracharya, B, Dongol, S, Karkey, A, Baker, S, Dougan, G, Pitzer, VE, Neuzil, KM, Shrestha, S, Basnyat, B, Pollard, AJ

“…<br><strong> Methods<br></strong> We did a participant-masked and observer-masked individually randomised trial in Lalitpur, Nepal, in which 20 019 children aged 9 months to younger than 16 years were randomly assigned in a 1:1 ratio to receive a single dose of TCV (Typbar TCV, Bharat Biotech International, India) or capsular group A meningococcal conjugate vaccine (MenA). …”

Vaccine traceability: Key learnings from the supply chain initiative by manufacturers from emerging countries by Sonia Pagliusi, Yvette Madrid, Yudha Bramanti, Taufik Wilmansyah, Huilin Yu, Analia Acebal, Komarapuram R. Krishnamurthy, Venkatapathi Raju Pinnamaraju, Padmakar Jadhav, Rachel Park, Lingjiang Yang

Get full text

Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study by Abtin Heidarzadeh, Mohammadreza Amini Moridani, Saman Khoshmanesh, Samira Kazemi, Marziyeh Hajiaghabozorgi, Manoochehr Karami

“…Objectives: The present study was conducted to estimate the effectiveness of (BBIBP)-CorV (Sinopharm), ChAdOx1-S/nCoV-19 (AZD1222, Oxford-AstraZeneca), rAd26-rAd5 (Gam-COVID-Vac, Sputnik V), and BIV1-CovIran (COVIran Barekat) and BBV152 COVAXIN (Bharat Biotech) vaccines against hospitalization and death of COVID-19 in Guilan Province of Iran from May 22 to December 21, 2021. …”
Get full text

Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis. by Aashish Contractor, Shashikala Shivaprakash, Anjali Tiwari, Maninder Singh Setia, Tarang Gianchandani

“…<h4>Background</h4>India started its vaccination programme for Coronavirus-19 infection (COVID-19) on 16 January 2021 with CovishieldTM (Oxford/Astra Zeneca vaccine manufactured by Serum Institute of India) and Covaxin ® (Bharat Biotech, India). We designed the present study to study the effectiveness of vaccines for COVID-19 in prevention of breakthrough infections and severe symptomatic cases among health care workers in a real-life scenario in Mumbai, India. …”
Get full text

Health inequality in COVID-19 vaccination coverage by Mousa Ghelichi-Ghojogh, Rozhan Khezri, Fatemeh Rezaei, Somayeh Aljalili, Rohollah Valizadeh, Tella Sadighpour

“…Finally, the third category involved the inactivated viral vaccines such as Bharat Biotech, Sinopharm, and Sinovac (10). These vaccines and the new medications have been effective (11). …”
Get full text

Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models by Adrián Alonso Ruiz, Anna Bezruki, Erika Shinabargar, Kaitlin Large, Marcela Vieira, Iulia Slovenski, Yiqi Liu, Surabhi Agarwal, Anna Becker, Suerie Moon

“…Finally, “Small MIC Developers” CanSino, Bharat Biotech, Medigen, Finlay Institute and the Center for Genetic Engineering and Biotechnology (CGEB), exported relatively small volumes to a few MICs. …”
Get full text

Indian Biosimilars and Vaccines at Crossroads–Replicating the Success of Pharmagenerics by Sunita Panda, Puneet Kumar Singh, Snehasish Mishra, Sagnik Mitra, Priyabrata Pattnaik, Sanjib Das Adhikary, Ranjan K. Mohapatra

“…A very positive sign was the remarkable disposition during the COVID-19 pandemic by Bharat Biotech and the Serum Institute of India. India’s biopharmaceutical industry has been instrumental in producing and supplying preventives and therapeutics to fight COVID-19. …”
Get full text

Safety and Immunogenicity Outcomes of an Inactivated Viral Vaccine against SARS-CoV-2 (Covaxin®) by Parul Sinha, Megha Gupta, Varunika Vijayvergia, Sushil Kumar Jain, Dinesh Kumar Jain, Sandeep Gupta, Monika Rathore, Nitya Vyas

“…Introduction: Bharat Biotech International Ltd in partnership with National Institute of Virology (NIV), has developed an indigenous whole virion inactivated Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) viral vaccine BBV-152 (Covaxin®), formulated with Toll Like Receptors 7/8 agonist Imidazoquinoline (IMDG) molecule adsorbed to alum (Algel). …”
Get full text

The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs by Andrew Farlow, Els Torreele, Glenda Gray, Kiat Ruxrungtham, Helen Rees, Sai Prasad, Carolina Gomez, Amadou Sall, Jorge Magalhães, Piero Olliaro, Petro Terblanche

Get full text

Immunogenicity and efficacy of conjugated and unconjugated Vi-polysaccharide vaccines in the prevention of typhoid fever by Jin, C

“…</p> <p>The findings from this study represent the first efficacy results and comprehensive assessment of humoral immunity for the only WHO prequalified TCV - Vi-TT (Typbar-TCV, Bharat Biotech). These results contributed to a change in global health policies and funding prioritisation for TCVs. …”

Investigating novel mechanisms of immunity against enteric fever by Johnson, M

“…In 2018, a Vi-tetanus toxoid conjugate vaccine (Vi-TCV), manufactured by Bharat Biotech and targeting the Vi polysaccharide capsule of S. …”

Havoc caused by the SARS-CoV-2 Omicron (B.1.1.529) by Prithiviraj Nagarajan, Kumar Rangarajalu

“…Another source of concern is the use of newly developed vaccines such as Johnson & Johnson’s vaccine, Covishield of Oxford- Astra Zeneca’s Bharat Biotech’s, Covaxin, Novavax, Sinovac, Sinopharm, Pfizer-BioNTech, which are based solely on the original SARS-CoV-2 strain and have been reported to exhibit lower efficacy against this newer version of Omicron, particularly in the mild and moderate spectrum of the disease [6]. …”
Get full text

Signatures of cellular immunity after vaccination and challenge that associate with clinical outcome of Salmonella Typhi infection by Cross, D

“…Participants were randomised to receive either a single dose of Vi-TT (Bharat Biotech), Vi-PS (Sanofi Pasteur) or a control vaccine, MenACWY (GlaxoSmithKline). …”